Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-02-21, Stock:LLY, The news for the past five days is as follows:
2019-02-13: NEWS1: Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report.NEWS2: Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report.NEWS3: Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report.NEWS4: Moat Index: Dramatic Sector Allocation Shift in 2018.NEWS5: J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod.NEWS6: J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod.NEWS7: The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion.NEWS8: The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion.NEWS9: 5 Tiny Biotech Stocks With Superb Growth Potential.NEWS10: 5 Tiny Biotech Stocks With Superb Growth Potential.NEWS11: What Are the Key Growth Drivers for Eli Lilly in Fiscal 2019?.NEWS12: J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod.NEWS13: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2019.NEWS14: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2019.NEWS15: The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion.NEWS16: Pfizer and Eli Lilly: How Dividends and Tax Rates Stack Up.NEWS17: 5 Tiny Biotech Stocks With Superb Growth Potential.NEWS18: Pfizer or Eli Lilly: Who Is Controlling Expenses Better?.NEWS19: Earnings Reaction History: Eli Lilly & Co., 50.0% Follow-Through Indicator, 2.4% Sensitive.NEWS20: Earnings Reaction History: Eli Lilly & Co., 50.0% Follow-Through Indicator, 2.4% Sensitive.
2019-02-14: NEWS1: Lilly To Participate in Leerink Partners Global Healthcare Conference.NEWS2: Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat.NEWS3: Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat.NEWS4: 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings.NEWS5: 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings.NEWS6: Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat.NEWS7: Thursday’s Vital Data: Eli Lilly, Twitter and Freeport-McMoRan.NEWS8: Thursday’s Vital Data: Eli Lilly, Twitter and Freeport-McMoRan.NEWS9: 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings.NEWS10: Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down.NEWS11: Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down.NEWS12: Thursday’s Vital Data: Eli Lilly, Twitter and Freeport-McMoRan.NEWS13: Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down.NEWS14: Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride.
2019-02-15: NEWS1: Elanco Animal Health Incorporated -- Moody's announces completion of a periodic review of ratings of Elanco Animal Health Incorporated.NEWS2: Health Care Sector Update for 02/15/2019: BSX,LLY,LOXO,ORPN,AKAO.NEWS3: Health Care Sector Update for 02/15/2019: BSX,LLY,LOXO,ORPN,AKAO.NEWS4: Primecap Management Trims Eli Lilly Position.NEWS5: Hagens Berman: Judge Denies Insulin Makers’ Motion to Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices.NEWS6: Health Care Sector Update for 02/15/2019: LLY,LOXO,ORPN,AKAO.NEWS7: Health Care Sector Update for 02/15/2019: LLY,LOXO,ORPN,AKAO.NEWS8: Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates.NEWS9: Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates.NEWS10: Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice.NEWS11: Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice.NEWS12: Bayer gains full Vitrakvi rights from Eli Lilly's Loxo.NEWS13: Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates.NEWS14: Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo.NEWS15: Lilly Completes Acquisition of Loxo Oncology.NEWS16: Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice.
2019-02-19: NEWS1: Eli Lilly and Co (LLY) Files 10-K for the Fiscal Year Ended on December 31, 2018.NEWS2: Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why.NEWS3: Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why.NEWS4: Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo.NEWS5: Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo.NEWS6: What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?.NEWS7: Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo.NEWS8: Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why.NEWS9: Pfizer-Lilly drug shown to help reduce back pain in late-stage trial.NEWS10: Higher dose of Pfizer-Lilly drug helps reduce back pain in study.NEWS11: Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain.
2019-02-20: NEWS1: Better Buy: Pfizer vs. Eli Lilly.NEWS2: Better Buy: Pfizer vs. Eli Lilly.NEWS3: Better Buy: Pfizer vs. Eli Lilly.NEWS4: Notable Wednesday Option Activity: LLY, DVN, IRM.NEWS5: Notable Wednesday Option Activity: LLY, DVN, IRM.NEWS6: Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study.NEWS7: Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study.NEWS8: Allergan Responds to Investor's Call for CEO/Chair Role Split.NEWS9: Allergan Responds to Investor's Call for CEO/Chair Role Split.NEWS10: Eli Lilly and Company -- Moody's assigns A2 rating to Eli Lilly's notes; stable outlook.NEWS11: Allergan Responds to Investor's Call for CEO/Chair Role Split.NEWS12: Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study.

Answer: Rise